Akebia Therapeutics (AKBA) Misses Q2 EPS by 9c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.60), $0.09 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $49.81 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Compass Point Starts Gorilla Tech Group/ (GRRR) at Buy
• Baidu (BIDU) Misses Q2 EPS by 262c, misses on revenue